Drupal.behaviors.print = function(context) {window.print();window.close();}>
Silence Puts Preclinical Cancer Drug on Back Burner to Advance Candidates with Newer Delivery Tech
November 10, 2011
Silence Puts Preclinical Cancer Drug on Back Burner to Advance Candidates with Newer Delivery Tech
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Silence Plans $28.6M Stock Sale to Fund Expansion of Staff, Pipeline
April 11, 2013 / Gene Silencing News
After Losing Another CEO, Silence Management Aims to Fill in Corporate Gaps
March 21, 2013 / Gene Silencing News
Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data
August 2, 2012 / Gene Silencing News
Silence Says Cash Runway Ends in Q3, Directors Have 'Uncertainty' About Additional Fundraising
March 22, 2012 / Gene Silencing News
With New CEO, Silence Looks to Find Partners and Advance a New Drug into the Clinic
February 16, 2012 / Gene Silencing News